Cell is heavy! American scientists develop a universal CAR-T system to treat cancer
Release date: 2018-05-02 Recently, scientists from MIT and Boston University have developed a universal CAR-T cell system, and the related research is published in "Cell", entitled "Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses" . Image source: Cell The highlights of the study are as follows: 1. Developed a separate, universal, and programmable (SUPRA) CAR system for T cell therapy; 2, SUPRA CAR can well regulate the degree of T cell activation to eliminate toxicity; 3. SUPRA CAR can sense multiple antigens and respond to fight cancer recurrence; 4. SUPRA CAR can induce signals that control cell type specificity. T cells expressing chimeric antigen receptors (CARs) are a promising cancer therapeutic drug with the potential to completely cure cancer. To expand the potential of the CAR T system to treat cancer, Professor Wilson W. Wong from MIT and colleagues developed a SUPRA CAR system that includes multiple upgrades, such as switching targets without reprogramming T cells. The degree of T cell activation is completely controllable, and multiple antigens can be sensed and a logical response can be made. These features can be used to combat tumor recurrence, eliminate overactivation and enhance the specificity of CAR T cell therapy. The researchers tested the system in two tumor models and found that the system exhibited a wide range of anticancer capabilities, so the system was considered to be humanized to reduce immunogenicity. In addition, the researchers extended an orthogonal SUPRA CAR system that independently regulates different T cell subsets, indicating that this is a dually inducible CAR system. Overall, these findings suggest that a variety of advanced logic and controllable features are suspectly integrated into a single integrated system, SUPRA CARs. Researchers hope that this CAR-T system will become a first-line drug against cancer in the early days, helping cancer patients improve their quality of life at an early date. Reference materials: Jang Hwan Cho, James J. Collins, Wilson W. Wong. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell.DOI: https://doi.org/10.1016/j.cell.2018.03.038 Source: Bio Valley Jiangsu Tiera Biotechnology Co., Ltd , https://www.tierabio.com